Embecta (EMBC) Stock Price, News & Analysis

Company Overview

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Key Stats

• Today's Range: $13.67 to $14.20
• 50-Day Range: $12.47 to $16.50
• 52-Week Range: $9.93 to $19.79
• Volume: 155,691 shs
• Average Volume: 401,457 shs
• Market Capitalization: $804.66 million
• P/E Ratio: 11.62
• Dividend Yield: 4.30%
• Price Target: $12.00
• Consensus Rating: Sell

Embecta Stock Analysis - MarketRank™

Embecta scored higher than 18% of companies evaluated by MarketBeat, and ranked 883rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Embecta has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Embecta has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -6.17%

Earnings Growth

Earnings for Embecta are expected to decrease by -6.17% in the coming year, from $2.43 to $2.28 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Embecta is 11.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of Embecta is 11.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.46.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.30% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Embecta has recently decreased by 3.28%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Leadership

Embecta is a leading dividend payer. It pays a dividend yield of 4.45%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Embecta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Embecta is 50.00%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Embecta will have a dividend payout ratio of 26.32% next year. This indicates that Embecta will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.30% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Embecta has recently decreased by 3.28%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Embecta this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Embecta insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.28% of the stock of Embecta is held by insiders.

Percentage Held by Institutions

93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EMBC Stock Analysis - Frequently Asked Questions

How have EMBC shares performed this year?

Embecta's stock was trading at $18.93 at the beginning of 2024. Since then, EMBC shares have decreased by 26.3% and is now trading at $13.9455.
View the best growth stocks for 2024 here.

How were Embecta's earnings last quarter?

Embecta Corp. (NASDAQ:EMBC) posted its quarterly earnings data on Friday, August, 9th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.28. The firm's quarterly revenue was down 4.8% compared to the same quarter last year.

Who are Embecta's major shareholders?

Top institutional shareholders of Embecta include River Road Asset Management LLC (6.03%), Yacktman Asset Management LP (4.38%), FMR LLC (4.17%) and State Street Corp (4.00%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann and David F Melcher.
View institutional ownership trends.

How do I buy shares of Embecta?

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Embecta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/09/2024
• Ex-Dividend for 9/13 Dividend: 8/27/2024
• Dividend Payable: 9/13/2024
• Today: 11/22/2024
• Next Earnings (Confirmed): 11/26/2024
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:EMBC
• CUSIP: N/A
• CIK: 1872789
• Web: www.embecta.com
• Phone: 201-847-6880
• Fax: N/A
• Employees: 2,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: -14.0%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.20
• Trailing P/E Ratio: 11.62
• Forward P/E Ratio: 5.74
• P/E Growth: N/A
• Net Income: $70.40 million
• Net Margins: 6.23%
• Pretax Margin: 5.02%
• Return on Equity: -19.09%
• Return on Assets: 12.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.11
• Quick Ratio: 1.61

Sales & Book Value

• Annual Sales: $1.12 billion
• Price / Sales: 0.72
• Cash Flow: $3.82 per share
• Price / Cash Flow: 3.65
• Book Value: ($14.34) per share
• Price / Book: -0.97

Miscellaneous

• Outstanding Shares: 57,700,000
• Free Float: 57,540,000
• Market Cap: $804.66 million
• Optionable: Optionable
• Beta: 0.97